Cargando…

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine

Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic information is available nowadays concerning desvenlafaxine, its active metabolite first marketed in 2012. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calleja, Sofía, Zubiaur, Pablo, Ochoa, Dolores, Villapalos-García, Gonzalo, Mejia-Abril, Gina, Soria-Chacartegui, Paula, Navares-Gómez, Marcos, de Miguel, Alejandro, Román, Manuel, Martín-Vílchez, Samuel, Abad-Santos, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934922/ https://www.ncbi.nlm.nih.gov/pubmed/36817149 http://dx.doi.org/10.3389/fphar.2023.1110460

Ejemplares similares

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety
por: Soria-Chacartegui, Paula, et al.
Publicado: (2023)

CYP2C8 *3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride
por: Campodónico, Diana María, et al.
Publicado: (2022)

PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride
por: Villapalos-García, Gonzalo, et al.
Publicado: (2023)

Patients’ Perceptions of Pharmacogenetic Testing and Access to Their Results: State of the Art in Spain and Systematic Review
por: Zubiaur, Pablo, et al.
Publicado: (2022)

Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline
por: Zubiaur, Pablo, et al.
Publicado: (2022)

Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism
por: Mejía-Abril, Gina, et al.
Publicado: (2021)

Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers
por: Casajús, Ana, et al.
Publicado: (2022)

Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin
por: Villapalos-García, Gonzalo, et al.
Publicado: (2021)

Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide
por: Soria-Chacartegui, Paula, et al.
Publicado: (2023)

Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2020)

Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2023)

Desvenlafaxine
por: Andrade, Chittaranjan
Publicado: (2009)

Combined Effects of UGT1A1 and SLCO1B1 Variants on Chinese Adult Mild Unconjugated Hyperbilirubinemia
por: Bai, Jie, et al.
Publicado: (2019)

Associations between UGT1A1 and SLCO1B1 polymorphisms and susceptibility to neonatal hyperbilirubinemia in Thai population
por: Atasilp, Chalirmporn, et al.
Publicado: (2022)

Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics
por: Koller, Dora, et al.
Publicado: (2020)

SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria
por: Sortica, Vinicius A, et al.
Publicado: (2017)

The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple‐dose trial
por: Koller, Dora, et al.
Publicado: (2020)

Desvenlafaxine in the treatment of major depressive disorder
por: Lourenco, Maria Teresa C, et al.
Publicado: (2009)

Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population
por: Vasilyev, Filipp Filippovich, et al.
Publicado: (2016)

Pharmacogenetics of Donepezil and Memantine in Healthy Subjects
por: Ovejero-Benito, María C., et al.
Publicado: (2022)

Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers
por: Aquilante, Christina L, et al.
Publicado: (2008)

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation
por: Ochoa, Dolores, et al.
Publicado: (2021)

Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations
por: Sychev, Dmitrij Alekseevitch, et al.
Publicado: (2017)

Author’s Response to: ‘Letter to the Editor in Response to: “Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally”’
por: Zubiaur, Pablo, et al.
Publicado: (2019)

Venlafaxine and desvenlafaxine in the management of menopausal hot flashes
por: Johnson, Emily D, et al.
Publicado: (2011)

The enhanced atorvastatin hepatotoxicity in diabetic rats was partly attributed to the upregulated hepatic Cyp3a and SLCO1B1
por: Shu, Nan, et al.
Publicado: (2016)

Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
por: Song, Gonjin, et al.
Publicado: (2021)

Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)
por: Zubiaur, Pablo, et al.
Publicado: (2020)

Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report
por: Dagli-Hernandez, Carolina, et al.
Publicado: (2021)

Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants
por: Lönnberg, K. Ivar, et al.
Publicado: (2023)

Regulation of High-Altitude Hypoxia on the Transcription of CYP450 and UGT1A1 Mediated by PXR and CAR
por: Duan, Ya-bin, et al.
Publicado: (2020)

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
por: Umland, Elena M, et al.
Publicado: (2012)

Drug–drug interactions involving antidepressants: focus on desvenlafaxine
por: Low, Yvette, et al.
Publicado: (2018)

Desvenlafaxine-Induced Interstitial Pneumonitis: A Case Report
por: Flora, Arjan, et al.
Publicado: (2018)

Characterization of CYPs and UGTs Involved in Human Liver Microsomal Metabolism of Osthenol
por: Cho, Pil Joung, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7n9t1agnu2fv3foviniet8a8jj